Table 3 Expression of studied genes in HCV-infected and non HCV-infected normal and malignant urothelium by real time PCR
Normal urothelium without HCV | Normal urothelium with HCV | Malignant urothelium without HCV | Malignant urothelium with HCV | |
|---|---|---|---|---|
Telomerase : | ||||
• hTERT by RT-PCR | 0.13 ± 0.05 | 2.37 ± 0.44a | 6.16 ± 0.57 ab | 11.88 ±1.34 abc |
• hTERT by IH (+ve cases) | 3 (6%) | 12 (24%) | 24 (48%) | 38 (76%) |
Mean labeled cells | 11.53 ± 2.82 | 14.90 ± 1.46 | 31.65 ± 9.02 | 44.36 ± 9.84 |
TRAP (ng/ml) | 0.54 ± 0.24 | 2.98 ± 0.59 a | 8.03 ± 1.26 ab | 15.88 ± 1.94 abc |
(positive cases) | 2 (4%) | 10 (20%) | 32 (64%) | 41 (82) |
Tumour suppressor genes: | ||||
• Rb by RT-PCR | 11.27 ± 1.42 | 6.92 ± 0.81 a | 2.75 ± 0.65 ab | 0.32 ± 0.30 abc |
• Rb by IH ( positive cases) | 3 (6%) | 12 (24%) | 26 (52%) | 40 (80%) |
• E2F3 by RT-PCR | 0.41 ±0.09 | 1.74 ± 0.47 a | 3.60 ±1.22 ab | 9.75 ± 4.32 abc |
• TP53 by RT-PCR | 0.25 ± 0.34 | 1.68 ± 0.29 a | 3.92 ± 0.46 ab | 12.39 ± 1.82 abc |
• p53 by IH (positive cases) | 0 (0%) | 3 (6%) | 21 (42%) | 42 (84) |
• P21 by RT-PCR | 9.80 ± 0.45 | 5.83 ± 0.86 a | 3.19 ± 0.45 ab | 0.25 ±0.34 abc |
• P21 by IH ( positive cases) | 49 (98%) | 31 (62%) | 13 (26%) | 3 (6%) |
Protooncogenes: | ||||
• FGFR3 by RT-PCR | 0.08 ± 0.12 | 0.86 ± 0.76 | 3.06 ± 2.45 ab | 2.87 ± 3.88 ab |
• FGFR3 by IH (positive cases) | 0 (0%) | 2 (4%) | 38 (76%) | 48 (96%) |